Business Context and Reporting Period
This Form 6-K filing by Redhill Biopharma Ltd. (Nasdaq: RDHL) covers the month of June 2026, with the report dated June 2, 2026. The filing incorporates a press release announcing that the Company is actively discussing potential collaborations to advance its investigational drug, opaganib, for the treatment of the current Ebola virus disease (EVD) outbreak involving the Bundibugyo sub-type. Discussions include the World Health Organization's (WHO) SOLIDARITY CORE clinical trial platform and potential partnerships with pharmaceutical companies.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics for the reporting period. The document focuses exclusively on clinical development updates and strategic discussions regarding opaganib.
Material Changes and Clinical Data
While no financial changes are reported, the filing highlights significant clinical and strategic developments regarding opaganib:
- Ebola Outbreak Response: Redhill is engaging with the WHO and other entities to evaluate opaganib as a host-directed therapy for the Bundibugyo EVD outbreak, where no approved medications currently exist.
- Clinical Evidence (COVID-19): The Company cites Phase 3 data showing a 70.2% mortality reduction when opaganib was added to standard of care (remdesivir + corticosteroids) in severe COVID-19 patients (6.98% mortality vs. 23.4% in placebo).
- Preclinical EVD Data: USAMRIID-funded studies indicated opaganib inhibits EVD in human macrophages and showed increased survival in one of two animal models. Synergistic effects were observed when combined with remdesivir.
- Mechanism of Action: Opaganib is a first-in-class SPHK2 inhibitor with a dual mechanism: it disrupts host-cell components essential for filovirus entry (PI3K/Akt pathway) and suppresses immune dysregulation (NLRP3 inflammasome, IL-6/TNFα).
Outlook, Risks, and Management Commentary
Management Commentary: Gilead Raday, COO and Head of R&D, emphasized the urgent need for options against the Bundibugyo outbreak. He highlighted opaganib's logistical advantages (oral administration, ease of storage) and its potential to complement direct-acting antivirals.
Outlook: The Company has provided supply readiness and safety data to facilitate rapid clinical exploration. Opaganib remains an investigational new drug with no regulatory approval for EVD or commercial distribution.
Risks and Contingencies:
- Regulatory Uncertainty: Inclusion in the WHO CORE platform is not guaranteed, and regulatory approval for EVD is not assured.
- Development Risks: There is a risk that opaganib may not demonstrate efficacy in EVD trials or that future studies may fail.
- Listing Compliance: The filing notes a risk regarding the Company's ability to regain and maintain compliance with Nasdaq listing requirements, specifically the minimum bid price.
- Funding: Risks exist regarding the continuity of U.S. government research and development funding.
Investor Verification Checklist
- Verify the status of discussions with the WHO SOLIDARITY CORE platform and whether a formal agreement has been reached.
- Confirm the Company's current cash position and runway, as this filing contains no financial data.
- Monitor Nasdaq compliance status regarding the minimum bid price requirement.
- Review the specific terms of the Bayer-supported Phase 2 study for opaganib in metastatic castrate-resistant prostate cancer (mCRPC).
- Assess the timeline for potential FDA Emergency Use Authorization (EUA) or other regulatory pathways for opaganib in EVD.